PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27354637-1	2016	BACKGROUND/AIM: For the application of invariant natural killer T (iNKT) cells in cancer therapy, the CD40-CD40L interaction is indispensable in administering alpha-galactosylceramide (alphaGalCer).	alpha-galactosylceramide	159-183	CD40 ligand	Mus musculus	107-112	
28912381-7	2017	alpha-Galactosylceramide treatment significantly enhanced expression of CD40L of lung iNKT cells from a mouse model of asthma, and the co-culture experiment of LDCs with iNKT cells showed the blockade of CD40L strongly suppressed surface maturation markers and proinflammatory cytokine production by LDCs.	alpha-galactosylceramide	0-24	CD40 ligand	Mus musculus	72-77	
28912381-7	2017	alpha-Galactosylceramide treatment significantly enhanced expression of CD40L of lung iNKT cells from a mouse model of asthma, and the co-culture experiment of LDCs with iNKT cells showed the blockade of CD40L strongly suppressed surface maturation markers and proinflammatory cytokine production by LDCs.	alpha-galactosylceramide	0-24	CD40 ligand	Mus musculus	204-209